Afzelia africana

Afzelia africana stem bark and seeds contain flavonoids, phenolics, alkaloids, anthraquinones, glycosides, terpenoids, and steroids—including the isolated compound 3,3'-di-O-methyl ellagic acid—that disrupt bacterial cell membranes and exert antiplasmodial activity. In vitro assays demonstrate killing of 95.8% of Escherichia coli and 99.1% of Bacillus pumilus cells within 105 minutes at 5 mg/ml, with antiplasmodial IC₅₀ values as low as 1.43 ± 0.072 μg/ml against Plasmodium falciparum strain 3D7.

Origin & History

Afzelia africana is a medium-to-large leguminous tree indigenous to the savanna woodlands and forest margins of West and Central Africa, including Nigeria, Ghana, Senegal, Cameroon, and Côte d'Ivoire. It thrives in well-drained lateritic soils under seasonal rainfall conditions typical of the Guinea and Sudan savanna zones, often growing to heights of 15–25 meters. The tree is not extensively cultivated commercially; bark, seeds, and pods are harvested from wild-growing specimens by traditional healers and local communities.

Historical & Cultural Context

Afzelia africana occupies a significant place in the ethnomedicinal traditions of West and Central African communities, where it is known as Apa-igbo in the Igbo-speaking regions of Nigeria and akpalata among Akan-speaking peoples of Ghana. Healers have long employed bark decoctions and seed preparations to address a wide spectrum of conditions including sexually transmitted infections such as gonorrhea, hernias, rheumatic pain, lumbago, malaria, and metabolic complaints including diabetes. The tree also holds cultural significance beyond medicine—its dense, durable hardwood has been used in carpentry and traditional crafts, making it a multi-use resource deeply embedded in local economies and knowledge systems. Ethnobotanical surveys conducted across Nigeria, Ghana, and neighboring countries have consistently documented these uses, providing the foundational data that has motivated laboratory investigation of the plant's bioactive constituents.

Health Benefits

- **Antibacterial Activity**: Aqueous and butanol fractions of stem bark extracts disrupt bacterial cell membranes, causing protein leakage from E. coli (6.5–9.8 μg/ml protein released within 3 hours at 5 mg/ml) and achieving MIC values of 0.313–2.5 mg/ml against multiple pathogen strains.
- **Antiplasmodial (Antimalarial) Potential**: Methanol bark fraction 1, rich in flavonoids, phenolics, steroids, and glycosides, shows potent in vitro activity against P. falciparum 3D7 with an IC₅₀ of 1.43 ± 0.072 μg/ml, well within the threshold for significant antimalarial activity.
- **Antioxidant Properties**: The isolated bark compound 3,3'-di-O-methyl ellagic acid demonstrates free-radical scavenging activity, likely through phenolic hydroxyl group donation, consistent with the broader ellagic acid class of polyphenols.
- **Traditional Gonorrhea and Urogenital Infection Management**: Ethnobotanical records from Igbo (Apa-igbo) and Akan (akpalata) communities document bark decoctions used to manage gonorrhea and related urogenital infections, plausibly mediated by the confirmed antibacterial bioactives.
- **Hernia and Musculoskeletal Pain Relief**: Traditional preparations in West African ethnomedicine employ bark and seed powders or decoctions topically and orally for hernia, lumbago, and rheumatism, with terpenoids and steroids among the phytochemical classes associated with anti-inflammatory mechanisms.
- **Hepatorenal Protective Effects**: Ethnobotanical reports indicate use for liver and kidney protection; the presence of phenolics and flavonoids with known antioxidative capacity in other species of the Leguminosae family supports a plausible cytoprotective mechanism, though direct evidence in A. africana remains unstudied.
- **Antidiabetic Potential**: Traditional use for blood-sugar management is documented, with alkaloids and terpenoids in the bark fractions representing phytochemical classes that in related leguminous species modulate glucose metabolism via enzyme inhibition (e.g., α-glucosidase), though this has not been confirmed experimentally for A. africana specifically.

How It Works

The antibacterial mechanism involves disruption of bacterial cell membrane integrity by phenolic compounds and terpenoids, resulting in measurable protein leakage—6.5 μg/ml from E. coli with aqueous fractions and 9.8 μg/ml with butanol fractions at 5 mg/ml within 3 hours—leading to 95.8% E. coli and 99.1% Bacillus pumilus cell death within 105 minutes. Antiplasmodial activity, particularly of fraction 1 (IC₅₀ 1.43 ± 0.072 μg/ml vs. P. falciparum 3D7), is attributed to the combined action of flavonoids, steroids, alkaloids, and phenolics, though specific molecular targets such as heme polymerization inhibition or dihydrofolate reductase suppression have not been experimentally confirmed in this species. The isolated compound 3,3'-di-O-methyl ellagic acid exerts antioxidant activity consistent with polyphenol-mediated radical scavenging via electron donation from aromatic hydroxyl groups, potentially also contributing to anti-inflammatory outcomes. ESI-MS analysis of bark fractions detects 14–37 major molecular ions per fraction, indicating chemical complexity that likely produces pleiotropic effects, but exact receptor binding affinities, enzyme inhibition constants, or gene expression data remain uncharacterized.

Scientific Research

The available scientific evidence for Afzelia africana consists entirely of in vitro studies—no animal pharmacokinetic studies, no randomized controlled trials, and no human clinical data have been published in accessible peer-reviewed literature. Antibacterial studies report MIC values of 0.313–2.5 mg/ml and MBC values of 0.625–5.0 mg/ml for stem bark extracts against bacterial strains including E. coli and B. pumilus, with time-kill kinetics measured at a single concentration point (5 mg/ml). Antiplasmodial bioassay-guided fractionation studies provide IC₅₀ data across four chromatographic fractions against P. falciparum 3D7, with fraction 1 (IC₅₀ 1.43 ± 0.072 μg/ml) showing activity comparable to established antimalarial leads, but the absence of selectivity index data, cytotoxicity assays, and mechanistic studies substantially limits interpretation. Phytochemical characterization studies have identified compound classes by colorimetric screening and ESI-MS profiling, with only one compound (3,3'-di-O-methyl ellagic acid) isolated and partially characterized for bioactivity, underscoring the early and highly preliminary nature of the scientific evidence base.

Clinical Summary

No human clinical trials have been conducted on Afzelia africana for any indication, including its traditional uses in gonorrhea, hernia, malaria, or rheumatism. All quantitative outcome data originate from cell-based and cell-free in vitro assays; no pharmacokinetic parameters, effective human doses, or patient-level effect sizes have been established. The antiplasmodial IC₅₀ of 1.43 ± 0.072 μg/ml for bark fraction 1 is a laboratory metric and cannot be directly extrapolated to clinical dosing or therapeutic efficacy in humans without bioavailability and toxicology data. Confidence in any clinical application is therefore very low, and the ingredient must be classified as at the earliest preclinical stage of pharmaceutical investigation.

Nutritional Profile

Afzelia africana has not been characterized for nutritional composition in peer-reviewed literature; no data on macronutrients, micronutrients, caloric content, or dietary fiber are available for its bark, seeds, or any processed form. Phytochemical profiling identifies flavonoids, phenolic acids, alkaloids, anthraquinones, glycosides, terpenoids, and steroids as the dominant secondary metabolite classes in methanol bark extracts. The isolated compound 3,3'-di-O-methyl ellagic acid represents a methylated derivative of ellagic acid, a polyphenol known in other plant species to have low oral bioavailability (estimated below 20% in humans for related forms) due to poor aqueous solubility and extensive first-pass metabolism. No quantitative concentration data in mg per gram of plant material have been published for any specific compound in this species, and bioavailability in humans is entirely unstudied.

Preparation & Dosage

- **Traditional Bark Decoction**: Stem bark is boiled in water to prepare an oral or topical decoction; exact volumes and concentrations vary by practitioner and region, with no standardized recipe documented in scientific literature.
- **Powdered Bark**: Dried and ground stem bark applied as a powder or dissolved in water; quantities used traditionally are unquantified in published studies.
- **Methanol Crude Extract (Research Context)**: In vitro studies employ concentrations of 0.313–5 mg/ml; these are laboratory-use concentrations and are not equivalent to human supplement doses.
- **Seed Preparations**: Seeds are used in some traditional systems, but no pharmacologically characterized preparation or dose has been reported.
- **Standardization**: No commercial standardized extract, capsule, or tincture form is established; no phytochemical standardization benchmarks (e.g., % flavonoids or ellagic acid) have been validated.
- **Human Dosing**: No safe or effective human dose has been determined by any regulatory body or clinical study; any use outside traditional ethnomedicinal contexts should be approached with extreme caution.

Synergy & Pairings

No experimental synergy data have been reported for Afzelia africana in combination with other botanical or pharmaceutical agents. Based on the phytochemical classes present—particularly flavonoids and phenolics—theoretical synergy with other antioxidant-rich botanical extracts such as those containing quercetin or ellagic acid derivatives is plausible via additive free-radical scavenging, but this has not been tested. Similarly, the antibacterial membrane-disrupting mechanism might theoretically complement cell-wall-targeting antibiotics, but no combination studies have been conducted, and such combinations should not be attempted without clinical data.

Safety & Interactions

No formal toxicological studies, side-effect profiles, or adverse event data have been published for Afzelia africana in either preclinical animal models or human subjects, meaning its safety cannot be established or assumed. In vitro experiments have not revealed overt cytotoxicity at the concentrations tested (0.313–5 mg/ml), but this does not constitute evidence of safety in vivo or at doses relevant to human consumption. No drug interaction data exist; however, the presence of alkaloids, anthraquinones, and flavonoids in the bark raises theoretical concerns about potential interactions with anticoagulants, antidiabetic medications, antimalarials, and hepatically metabolized drugs via cytochrome P450 pathways—none of which have been studied. Use during pregnancy and lactation is entirely unstudied and cannot be recommended; traditional use does not substitute for clinical safety evaluation, and no maximum safe dose has been established by any regulatory or scientific body.